In the A20 model, direct activation of B-lymphoma cells with G100 is sufficient to induce protective CD8 T-cell responses and TLR4 expressing human B-cell lymphomas may be amenable to this therapy as well. The gene discussed is CD8A; the disease is B-cell non-Hodgkin lymphoma.